Iris Long, chemist who helped ACT UP speed AIDS drug approvals, dies at 92

Iris Long gave ACT UP something most protest movements lack: fluency in the science. As a retired pharmaceutical chemist in Queens, she helped fellow activists make sense of drug trials, the FDA and the machinery of drug development, turning anger over the AIDS crisis into disciplined treatment activism that helped push national policy.

Long died on April 4, 2026, at age 92. Born in New York City on December 8, 1934, she studied chemistry at Hunter College and later became one of the rare scientifically trained voices inside ACT UP, the AIDS Coalition to Unleash Power, which formed in New York City in 1987 as a political action group confronting the epidemic.

ACT UP’s first major action came that spring, when members marched on Wall Street to protest the high cost and limited availability of HIV drugs. Long’s role was less visible than a megaphone or banner, but no less important. She helped activists read clinical data, understand how the FDA evaluated experimental drugs and challenge the slow pace of development with arguments rooted in evidence rather than outrage alone.

That combination proved decisive. ACT UP’s treatment-access work helped drive the parallel-track concept, allowing some patients broader access to experimental drugs, and contributed to later reforms that shortened AIDS drug approval pathways. The group’s strategy showed how a movement could pair direct action with technical literacy to force institutions to move faster.

Long’s place in that history was documented in an ACT UP oral history recorded on May 16, 2003, which focused on the FDA, the CDC definition of AIDS and women and AIDS. Her role also surfaced in accounts from activists who remembered her as a steady teacher inside a movement often defined by confrontation. She was part of ACT UP’s treatment and data committee, where scientific detail became political leverage.

Tributes from HIV and AIDS advocates after her death reflected what Long represented: a bridge between the laboratory and the street, and a model for patient activism that still shapes medicine. ACT UP’s legacy was not just protest. It was protest informed by science, and Iris Long helped make that possible.